EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Withaferin A Attenuates Muscle Cachexia Induced by Angiotensin II Through Regulating Pathways Activated by Angiotensin II

Sham S Kakar, Vasa Vemuri iD, Mariusz Z Ratajczak iD

Cells · 2025

DOI: 10.3390/cells14040244 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Sham S Kakar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, University of Louisville, Louisville, KY 40202, USA. Hauptthemen laut MEDLINE: Withanolides, Cachexia, Angiotensin II, Signal Transduction. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NHLBI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cachexia is a multifactorial syndrome characterized by severe muscle wasting and is a debilitating condition frequently associated with cancer. Previous studies from our group revealed that withaferin A (WFA), a steroidal lactone, mitigated muscle cachexia induced by ovarian tumors in NSG mice. However, it remains unclear whether WFA’s protective effects are direct or secondary to its antitumor properties. We developed a cachectic model through continuous angiotensin II (Ang II) infusion in C57BL/6 mice to address this issue. Ang II infusion resulted in profound muscle atrophy, evidenced by significant reductions in grip strength and in the TA, GA, and GF muscle mass. Molecular analyses indicated elevated expression of inflammatory cytokines (TNFα, IL-6, MIP-2, IL-18, IL-1β), NLRP3 inflammasome, and genes associated with the UPS (MuRF1, MAFBx) and autophagy pathways (Bacl1, LC3B), along with suppression of anti-inflammatory heme oxygenase-1 (HO-1) and myogenic regulators (Pax7, Myod1). Strikingly, WFA treatment reversed these pathological changes, restoring muscle mass, strength, and molecular markers to near-normal levels. These findings demonstrate that WFA exerts direct anti-cachectic effects by targeting key inflammatory and atrophic pathways in skeletal muscle, highlighting its potential as a novel therapeutic agent for cachexia management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

WithanolidesCachexiaAngiotensin IISignal TransductionAnimalsMice, Inbred C57BLMiceMuscle, SkeletalMuscular AtrophyAutophagyCytokinesFemaleNLR Family, Pyrin Domain-Containing 3 ProteinInflammasomes

Stichwörter der Autor:innen

Ang IIcytokinesmuscle cachexiamuscle functionwithaferin A

Substanzen

withaferin AWithanolidesAngiotensin IICytokinesNLR Family, Pyrin Domain-Containing 3 ProteinInflammasomes

Autor:innen und Institutionen

  • Department of Physiology, University of Louisville, Louisville, KY 40202, USA.
  • Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA.
  • Department of Medicine, University of Louisville, Louisville, KY 40202, USA.

ORCID-Profile: Vasa Vemuri, Mariusz Z Ratajczak

Förderung

  • NIGMS NIH HHS
  • NHLBI NIH HHS
  • NIH HHS
  • National Institute of Health

Zitieren

APA

Kakar, S. S., Vemuri, V., & Ratajczak, M. Z. (2025). Withaferin A Attenuates Muscle Cachexia Induced by Angiotensin II Through Regulating Pathways Activated by Angiotensin II. Cells. https://doi.org/10.3390/cells14040244

Vancouver

Kakar SS, Vemuri V, Ratajczak MZ. Withaferin A Attenuates Muscle Cachexia Induced by Angiotensin II Through Regulating Pathways Activated by Angiotensin II. Cells. 2025. doi:10.3390/cells14040244

BibTeX
@article{Kakar2025,
  author = {Kakar, Sham S and Vemuri, Vasa and Ratajczak, Mariusz Z},
  title = {Withaferin A Attenuates Muscle Cachexia Induced by Angiotensin II Through Regulating Pathways Activated by Angiotensin II},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14040244}
}
Kostenlos starten →